GHK-Cu is the copper(II) complex of a short, naturally occurring tripeptide — glycyl-L-histidyl-L-lysine, abbreviated GHK. It is best understood as a copper-binding peptide: the sequence carries a built-in affinity for copper ions, and the resulting peptide–metal complex is the molecule studied in the laboratory literature. This overview covers what GHK-Cu is at the structural level, the copper-binding chemistry that defines it, the mechanisms research has focused on, and what specific published studies actually measured in their experimental models. The compound is available on its GHK-Cu product page, and the same molecule appears as a component of two multi-peptide research blends discussed near the end of this article.
What GHK-Cu is
At its core, GHK is a tripeptide — a chain of just three amino acids: glycine, L-histidine, and L-lysine, in that order (Gly-His-Lys). It was originally isolated from human plasma, which makes it a naturally occurring sequence rather than a designed drug. The “-Cu” suffix denotes that the peptide is supplied as a complex with a single copper(II) ion, written chemically as GHK-Cu2+. The copper is not an incidental additive — it is the defining feature of the molecule, because the biochemistry researchers have studied is, in large part, the biochemistry of a peptide-bound copper ion being carried into a biological system.
Structurally, GHK-Cu has two parts that always travel together: the small tripeptide scaffold and the metal ion it chelates. That pairing is why the compound is described as a copper peptide, and why the literature regards the copper-binding behavior as central rather than peripheral.
The copper-binding chemistry that defines it
The reason GHK binds copper so well comes down to its middle residue. Histidine carries an imidazole side chain whose nitrogen atoms are strong coordinating groups for transition-metal ions, and in GHK that histidine sits flanked by the free amino terminus of glycine and the side-chain amine of lysine. Together these donor atoms form a coordination geometry that wraps around a copper(II) ion and holds it in a stable square-planar arrangement. The result is a high-affinity complex: GHK does not merely sit near copper, it chelates it.
This chelation gives GHK-Cu its distinct identity. Free copper ions are reactive and tightly controlled in biological systems, whereas peptide-bound copper is presented in a more regulated form. In the research literature, GHK-Cu is frequently framed as a physiological copper-binding peptide that participates in copper-dependent biochemistry. Because the metal and the peptide function as a single unit, studies almost always describe the complexed GHK-Cu form rather than the bare peptide.
The mechanisms research focuses on
Two broad mechanistic themes dominate the published GHK-Cu literature, and both are described here strictly as what investigators measured in cell, tissue, and animal models — not as outcomes attributed to any person.
The first theme is extracellular-matrix (ECM) and collagen remodeling. In fibroblast and wound models, researchers have measured changes in the production and turnover of matrix components — collagen, glycosaminoglycans, proteoglycans — and in the enzymes that remodel that matrix. The work positions GHK-Cu as a molecule that experimental systems respond to with altered ECM-related activity.
The second theme is broad gene-expression modulation. Transcriptome-scale analyses — including work that ran GHK against the Broad Institute Connectivity Map, a large database of gene-expression signatures — reported that the peptide is associated with shifts in the expression of a wide set of genes in cultured human cells. This is the angle emphasized in Pickart’s reviews: rather than a single target, the published gene data describe GHK as a modulator registered across many transcriptional pathways at once. In every case the measurement belongs to the cited model, and the citation is the claim.
What published research measured
The following points summarize specific findings from the peer-reviewed literature. Each describes a measurement made in a defined research model, with its citation:
- In cultured dermal fibroblasts, the tripeptide-copper complex was reported to increase levels of matrix metalloproteinase-2 (MMP-2), an enzyme involved in extracellular-matrix remodeling, in conditioned media (Siméon et al., Life Sci, 2000).
- In an experimental wound model, GHK-Cu treatment was associated with modulated mRNA levels of the small proteoglycans decorin and biglycan and altered glycosaminoglycan expression during repair (Siméon et al., J Invest Dermatol, 2000).
- A review of GHK-Cu biochemistry catalogued cell- and tissue-model reports of effects on the expression of genes tied to collagen, elastin, and glycosaminoglycan synthesis and to tissue remodeling (Pickart & Margolina, BioMed Research International, 2015).
- A later review synthesized transcriptome-scale gene data, summarizing Connectivity Map analyses in which GHK was associated with shifts across a large number of human genes (Pickart & Margolina, Int J Mol Sci, 2018).
- A focused analysis examined GHK’s association with the expression of genes relevant to nervous-system function, again drawing on Connectivity Map gene-expression signatures (Pickart et al., Brain Sci, 2017).
Taken together, these are descriptions of laboratory observations — what the molecule did in fibroblast cultures, wound models, and transcriptome databases — not statements about effects in people.
How GHK-Cu relates to the GLOW and KLOW blends
GHK-Cu is sold both on its own and as one ingredient inside two multi-component research blends, which is why it surfaces in searches for those products. The relationship is purely additive at the level of ingredients:
- GLOW pairs GHK-Cu with BPC-157 and TB-500 — three chemically unrelated peptides supplied in one vial. The chemistry of each is covered in our explainer, What Is the GLOW Stack?
- KLOW is the same three plus a fourth peptide, KPV, a lysine-proline-valine tripeptide. Its components are broken down in What Is the KLOW Blend?
In both blends, GHK-Cu contributes exactly the copper-binding tripeptide described above; the blend name is simply an acronym for the components co-located together, not a description of any combined result. If a study design calls only for the copper peptide on its own, the standalone GHK-Cu is the relevant material.
Frequently asked questions
What does GHK-Cu stand for?
GHK-Cu denotes the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. “GHK” is the single-letter shorthand for that glycine–histidine–lysine amino-acid sequence, and “Cu” is the chemical symbol for copper, the metal ion the peptide binds.
Why is copper part of the molecule?
The histidine residue in the middle of the GHK sequence has an imidazole side chain that coordinates copper(II) ions strongly. The peptide therefore chelates a copper ion to form a stable complex, and that complexed GHK-Cu form — not the bare peptide — is what the research literature studies.
Is GHK-Cu naturally occurring?
The underlying GHK tripeptide was originally isolated from human plasma and has also been reported in saliva and urine, so the sequence occurs naturally. The material supplied for research is produced synthetically and complexed with copper.
What have studies measured with GHK-Cu?
Published work has measured changes in extracellular-matrix activity — for example matrix metalloproteinase-2, glycosaminoglycans, and the proteoglycans decorin and biglycan — in fibroblast and wound models, plus broad shifts in gene expression in transcriptome analyses. These are findings within those specific research models.
How is GHK-Cu different from GHK?
GHK is the tripeptide on its own; GHK-Cu is that same tripeptide bound to a copper(II) ion. Because the copper-binding behavior is central to the biochemistry researchers study, the literature generally refers to the copper-complexed GHK-Cu form.
Is GHK-Cu approved for human use?
No. GHK-Cu is a research compound characterized in laboratory, cell, and animal models, and the product discussed here is intended for laboratory research purposes only, not for human or veterinary use.
References
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. PMID: 29986520.
- Pickart L, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015. PMID: 26236730.
- Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sci. 2017. PMID: 28212278.
- Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000. PMID: 11045606.
- Siméon A, Wegrowski Y, Bontemps Y, Maquart FX. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 2000. PMID: 11121126.
For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.
